Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EXACT Therapeutics AS Board/Management Information 2021

Jan 29, 2021

3600_rns_2021-01-29_e9ee5a33-91a5-4b31-b25b-a371375f8134.html

Board/Management Information

Open in viewer

Opens in your device viewer

EXACT THERAPEUTICS ANNOUNCES CHANGE OF CFO WITH DEPARTURE OF STIG JARLE PETTERSEN AT THE END OF HIS CONTRACTED PERIOD

EXACT THERAPEUTICS ANNOUNCES CHANGE OF CFO WITH DEPARTURE OF STIG JARLE PETTERSEN AT THE END OF HIS CONTRACTED PERIOD

OSLO/LONDON, JANUARY 29th 2021: EXACT THERAPEUTICS AS (“EXACT-Tx” or the “Company”), a clinical stage precision medicine company today announced that the company’s CFO Stig Jarle Pettersen, engaged as a part time consultant via his company CFO For Hire AS, will leave the company on January 31st 2021 at the end of his contracted period. EXACT Tx thanks Stig for his valuable contribution since joining the company in January 2019 and in particular for his support during the successful financing and listing on the Merkur Market (Euronext growth) in July 2020.

The process of hiring a full time CFO is ongoing and Ole Fegth of Abaci AS will assume CFO responsibilities for the company until ad interim.

About EXACT

EXACT-Tx is a clinical stage Norwegian biotech company developing a technology platform for targeted therapeutic enhancement – Acoustic Cluster Therapy (ACT®). ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug enhancement – with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. www.exact-tx.com

For more information contact:

Dr Rafiq Hasan

CEO EXACT Therapeutics

[email protected]

Richard Hayhurst/Janet Joy

Tel +44 7711 821527

[email protected]